Predicting nanocarrier permeation across the human intestinein vitro: Model matters

Abstract

For clinical translation of oral nanocarriers, simulation of the complex intestinal microenvironment is crucial to evaluate interactions and transport across the intestinal mucosa for predicting the drug’s bioavailability. However, permeation studies are often conducted using simplistic cell culture models, overlooking key physiological factors such as tissue composition, morphology, and additional diffusion barriers as constituted by mucus. This oversight may potentially lead to an incomplete evaluation of the nanocarrier-tissue interactions and an overestimation of permeation. In this study, we systematically investigated different 3D tissue models of the human intestine under static cultivation and dynamic flow conditions with respect to tissue morphology, mucus production, and their impact on nanocarrier permeation. Our results revealed that the cell ratio between the different cell types (enterocytes and goblet cells), as well as the choice of culture conditions, had a notable impact on tissue layer thickness, mucus secretion, and barrier impairment, all of which were increased under dynamic flow conditions. Permeation studies with polymeric nanocarriers (PLGA and PEG-PLGA) elucidated that the amount of mucus present in the respective model was the limiting factor for the permeation of PLGA nanocarriers, while tissue topography represented the key factor influencing PEG-PLGA nanocarrier permeation. Furthermore, both nanocarriers exhibited diametrically opposite permeation kinetics in a direct comparison to soluble compounds. In summary, these findings reveal the critical role of the implemented test systems on permeation assessment and emphasize that, in the context of preclinical nanocarrier testing, the choice ofin vitromodel matters.